Hira S Mian1, Tanya M Wildes1, Mark A Fiala1. 1. Hira S. Mian, McMaster University, Hamilton, Ontario, Canada; and Tanya M. Wildes and Mark A. Fiala, Washington University School of Medicine, St. Louis, MO.
Abstract
Purpose: To develop a frailty index using the Rockwood Accumulation of Deficits approach for the Medicare Health Outcomes Survey (MHOS) and apply it in a subset of older patients with newly diagnosed multiple myeloma. Methods: Data from 2,692,361 patients without cancer, > 66 years of age, in SEER-MHOS linked databases between 1998 and 2009 were analyzed. A frailty index was constructed, resulting in a 25-item scale; cutoff values were created for individuals classified as frail. This frailty index was then applied to 305 patients with newly diagnosed myeloma in the database to predict overall survival. Results: In the derivation cohort of patients without cancer, the median age was 74 years and the mean frailty index was 0.23 (standard deviation, 0.17). Among patients without cancer, each 10% increase in frailty index (approximately three to four more deficits) was associated with a 40% increased risk for death (adjusted hazard ratio, 1.397; 95% CI, 1.396 to 1.399; P < .001). In the cohort of patients with newly diagnosed myeloma, the median age was 76 years an d the mean frailty index was 0.28 (standard deviation, 0.17). Each 10% increase in frailty index was associated with a 16% increased risk for death (adjusted hazard ratio, 1.159; 95% CI, 1.080 to 1.244; P < .001). Fifty-three percent of patients with multiple myeloma were considered frail. The estimated median overall survival of patients considered frail was 26.8 months, compared with 43.7 months (P = .015) for those who were not. Conclusion: The MHOS-based frailty index was prognostic for patients with multiple myeloma in predicting overall survival.
Purpose: To develop a frailty index using the Rockwood Accumulation of Deficits approach for the Medicare Health Outcomes Survey (MHOS) and apply it in a subset of older patients with newly diagnosed multiple myeloma. Methods: Data from 2,692,361 patients without cancer, > 66 years of age, in SEER-MHOS linked databases between 1998 and 2009 were analyzed. A frailty index was constructed, resulting in a 25-item scale; cutoff values were created for individuals classified as frail. This frailty index was then applied to 305 patients with newly diagnosed myeloma in the database to predict overall survival. Results: In the derivation cohort of patients without cancer, the median age was 74 years and the mean frailty index was 0.23 (standard deviation, 0.17). Among patients without cancer, each 10% increase in frailty index (approximately three to four more deficits) was associated with a 40% increased risk for death (adjusted hazard ratio, 1.397; 95% CI, 1.396 to 1.399; P < .001). In the cohort of patients with newly diagnosed myeloma, the median age was 76 years an d the mean frailty index was 0.28 (standard deviation, 0.17). Each 10% increase in frailty index was associated with a 16% increased risk for death (adjusted hazard ratio, 1.159; 95% CI, 1.080 to 1.244; P < .001). Fifty-three percent of patients with multiple myeloma were considered frail. The estimated median overall survival of patients considered frail was 26.8 months, compared with 43.7 months (P = .015) for those who were not. Conclusion: The MHOS-based frailty index was prognostic for patients with multiple myeloma in predicting overall survival.
Authors: Antonio Palumbo; Sara Bringhen; Heinz Ludwig; Meletios A Dimopoulos; Joan Bladé; Maria V Mateos; Laura Rosiñol; Mario Boccadoro; Michele Cavo; Henk Lokhorst; Sonja Zweegman; Evangelos Terpos; Faith Davies; Christoph Driessen; Peter Gimsing; Martin Gramatzki; Roman Hàjek; Hans E Johnsen; Fernando Leal Da Costa; Orhan Sezer; Andrew Spencer; Meral Beksac; Gareth Morgan; Hermann Einsele; Jesus F San Miguel; Pieter Sonneveld Journal: Blood Date: 2011-08-12 Impact factor: 22.113
Authors: Harvey Jay Cohen; David Smith; Can-Lan Sun; William Tew; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Julie Filo; Vani Katheria; Arti Hurria Journal: Cancer Date: 2016-08-16 Impact factor: 6.860
Authors: Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz Journal: Blood Date: 2007-11-01 Impact factor: 22.113
Authors: Monika Engelhardt; Anne-Saskia Domm; Sandra Maria Dold; Gabriele Ihorst; Heike Reinhardt; Alexander Zober; Stefanie Hieke; Corine Baayen; Stefan Jürgen Müller; Hermann Einsele; Pieter Sonneveld; Ola Landgren; Martin Schumacher; Ralph Wäsch Journal: Haematologica Date: 2017-02-02 Impact factor: 9.941
Authors: Nadia A Nabulsi; Ali Alobaidi; Brian Talon; Alemseged A Asfaw; Jifang Zhou; Lisa K Sharp; Karen Sweiss; Pritesh R Patel; Naomi Y Ko; Brian C-H Chiu; Gregory S Calip Journal: Cancer Causes Control Date: 2020-04-30 Impact factor: 2.506
Authors: Rasheeda K Hall; Sarah Morton; Jonathan Wilson; Dae Hyun Kim; Cathleen Colón-Emeric; Julia J Scialla; Alyssa Platt; Patti L Ephraim; L Ebony Boulware; Jane Pendergast Journal: Kidney360 Date: 2022-07-19
Authors: Nadia A Nabulsi; Khatija W Naing; Huiwen Deng; Jenilee Cueto; Alemseged A Asfaw; Colin C Hubbard; Jifang Zhou; Inyoung Lee; Debanjali Mitra; Gregory S Calip; Ernest H Law Journal: J Patient Exp Date: 2022-07-11
Authors: Mary M Mullen; Tyler R McKinnish; Mark A Fiala; Abigail S Zamorano; Lindsay M Kuroki; Katherine C Fuh; Andrea R Hagemann; Carolyn K McCourt; David G Mutch; Matthew A Powell; Tanya M Wildes; Premal H Thaker Journal: Gynecol Oncol Date: 2021-02-26 Impact factor: 5.304
Authors: Chandler Coleman; Connie H Yan; Naomi Y Ko; Nadia A Nabulsi; Kent F Hoskins; Brian C-H Chiu; Gregory S Calip Journal: Breast Date: 2022-04-14 Impact factor: 4.254